Bessemer Group Inc. grew its position in shares of argenex SE (NASDAQ:ARGX – Free Report) by 2.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 64,251 shares of the company’s stock after acquiring an additional 1,714 shares during the period. Bessemer Group Inc.’s holdings in argenex were worth $46,920,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of ARGX. Oppenheimer & Co. Inc. lifted its holdings in argenex by 2.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock worth $372,000 after buying an additional 12 shares during the period. Valeo Financial Advisors LLC boosted its holdings in shares of argenex by 0.9% during the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock valued at $1,153,000 after buying an additional 12 shares in the last quarter. CI Investments Inc. grew its position in shares of argenex by 2.6% in the 4th quarter. CI Investments Inc. now owns 469 shares of the company’s stock worth $394,000 after buying an additional 12 shares during the period. Allworth Financial LP increased its stake in shares of argenex by 12.7% in the 4th quarter. Allworth Financial LP now owns 115 shares of the company’s stock worth $97,000 after acquiring an additional 13 shares in the last quarter. Finally, WPG Advisers LLC increased its stake in shares of argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after acquiring an additional 13 shares in the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research analysts recently issued reports on the stock. Royal Bank Of Canada lifted their price target on shares of argenex from $890.00 to $945.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Glj Research raised shares of argenex to a “strong-buy” rating in a research note on Friday, April 3rd. Guggenheim lifted their target price on shares of argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a report on Friday, May 8th. Oppenheimer dropped their price target on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research report on Thursday, April 2nd. Finally, Wells Fargo & Company boosted their price target on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, argenex presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,037.61.
argenex Stock Performance
Shares of ARGX stock opened at $860.55 on Friday. The company has a market capitalization of $53.52 billion, a price-to-earnings ratio of 38.31, a price-to-earnings-growth ratio of 1.06 and a beta of 0.45. argenex SE has a one year low of $560.91 and a one year high of $953.58. The company’s 50-day moving average is $860.97 and its 200 day moving average is $813.59.
argenex (NASDAQ:ARGX – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. The business had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. As a group, research analysts predict that argenex SE will post 26.27 earnings per share for the current fiscal year.
argenex Company Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
Featured Articles
- Five stocks we like better than argenex
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX – Free Report).
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
